BIO-RAD LABORATORIES, INC.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $2.6B | $2.6B | $2.7B | $2.8B | $2.9B |
| Gross profit | $1.3B | $1.4B | $1.4B | $1.6B | $1.6B |
| Operating income | $47.2M | $269.0M | $337.8M | $482.6M | $500.3M |
| Cost of revenue | $1.2B | $1.2B | $1.2B | $1.2B | $1.3B |
| Cash from operations | $532.2M | $455.2M | $374.9M | $194.4M | $669.5M |
| Capital expenditure | $157.6M | $165.6M | $156.7M | $112.8M | $133.7M |
| Free cash flow | $374.6M | $289.6M | $218.2M | $81.6M | $535.7M |
| Share repurchases | $295.5M | $203.6M | $428.7M | $215.7M | $50.0M |
| Impairments | $172.8M | $0 | $0 | $0 | $0 |
| Total assets | $10.6B | $9.4B | $12.3B | $13.5B | $17.8B |
| Total liabilities | $3.1B | $2.8B | $3.6B | $3.9B | $4.1B |
Shares outstanding 26.8M · Free float 37.6%
Annual filing data through FY ended December 31, 2025; float as of July 8, 2026.